ASH 2020 | Real-world data on treatment strategies and outcomes in systemic AL amyloidosis
Efstathios Kastritis
• 11 Dec 2020
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, outlines the results of the ongoing retrospective EMN23 study, analyzing real-world efficacy outcomes for patients with systemic immunoglobin light chain (AL) amyloidosis. The aim of the EMN23 study is to thoroughly describe patterns of AL amyloidosis management in a large-scale real-world setting throughout Europe and to understand different treatment strategies and their evolution over time. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
